Findings from a Cochrane review reveal that patients suffering from the autoimmune disease multiple sclerosis (MS) who took anti-inflammatory drug natalizumab for two years exhibited a reduction in relapse rate and progression of disability.
Dr Doug Brown, Head of Biomedical Research at theMS Society, said, "Natalizumab is a licensed treatment for MS in the UK and we have known for some time that it reduces relapse rates and progression o